(ALTUV) BIO UV - Ratings and Ratios

Exchange: PA • Country: France • Currency: EUR • Type: Common Stock • ISIN: FR0013345493

ALTUV: Water, Treatment, Devices, Disinfectant, UV, Systems, Purifiers

BIO-UV Group S.A. is a France-based company specializing in UV light-based water treatment and surface disinfection solutions. Since its inception in 2000, the company has developed a diverse portfolio of products tailored for residential, commercial, and industrial applications. Its offerings include systems for swimming pools, drinking water treatment, wastewater disinfection, and industrial process water management. BIO-UV Group also addresses niche markets such as aquaculture, maritime ballast water treatment, and surface disinfection in public and medical settings.

The companys product range includes OClear UV for drinking water, DELTA-UV for pools, and BIO-SEA for maritime applications. Additionally, BIO-UV Group provides solutions for specific industrial needs, such as RW systems for municipal wastewater and IBP systems for industrial processes. Its surface disinfection products, like BIO-SCAN LIGHT, cater to healthcare and public spaces. The company serves clients across Europe, Asia, the Middle East, and the Americas, with a strong focus on innovation and environmental sustainability.

Based on the provided and , here is a 3-month forecast: The stock price of BIO-UV Group (ALTUV) is expected to experience sideways movement with a slight bearish bias. The SMA 20 (1.99) is below the SMA 50 (2.11) and SMA 200 (2.01), indicating potential weakness. The ATR of 0.04 suggests low volatility, so price fluctuations are likely to be minimal. Support is anticipated around the SMA 200 level of 2.01, with resistance near the SMA 50 at 2.11. The low average volume of 9,839 shares could lead to thin trading, affecting short-term price movements. Fundamental analysis shows a high P/E ratio of 61.00, suggesting caution, while the P/S ratio of 0.65 indicates undervaluation relative to sales. The companys focus on water treatment and disinfection aligns with growing environmental concerns, which may positively influence long-term prospects.

Additional Sources for ALTUV Stock

Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle

ALTUV Stock Overview

Market Cap in USD 28m
Sector Industrials
Industry Pollution & Treatment Controls
GiC Sub-Industry Environmental & Facilities Services
IPO / Inception

ALTUV Stock Ratings

Growth 5y -73.7%
Fundamental 39.9%
Dividend 1.0%
Rel. Strength -25.8
Analysts -
Fair Price Momentum 1.28 EUR
Fair Price DCF 10.47 EUR

ALTUV Dividends

Dividend Yield 12m 0.00%
Yield on Cost 5y %
Annual Growth 5y -100.00%
Payout Consistency 26.4%

ALTUV Growth Ratios

Growth Correlation 3m -91.7%
Growth Correlation 12m -50.1%
Growth Correlation 5y -94.7%
CAGR 5y -16.03%
CAGR/Max DD 5y -0.20
Sharpe Ratio 12m -0.45
Alpha -30.90
Beta 0.382
Volatility 46.78%
Current Volume 39.8k
Average Volume 20d 7k
What is the price of ALTUV stocks?
As of April 09, 2025, the stock is trading at EUR 1.62 with a total of 39,789 shares traded.
Over the past week, the price has changed by -11.79%, over one month by -11.50%, over three months by -31.15% and over the past year by -29.50%.
Is BIO UV a good stock to buy?
Partly, yes. Based on ValueRay Fundamental Analyses, BIO UV (PA:ALTUV) is currently (April 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 39.87 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ALTUV as of April 2025 is 1.28. This means that ALTUV is currently overvalued and has a potential downside of -20.99%.
Is ALTUV a buy, sell or hold?
BIO UV has no consensus analysts rating.
What are the forecast for ALTUV stock price target?
According to ValueRays Forecast Model, ALTUV BIO UV will be worth about 1.4 in April 2026. The stock is currently trading at 1.62. This means that the stock has a potential downside of -14.81%.
Issuer Forecast Upside
Wallstreet Target Price 3.6 122.2%
Analysts Target Price - -
ValueRay Target Price 1.4 -14.8%